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CLINICS IN SPORTS MEDICINEPrevention of Infectious Diseases
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Primary Care Sports Medicine, University of California San Francisco, 500 Parnassus Ave.,
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I
nfections in sports can be serious medical problems. They can affect individ-
ual athletes, resulting in morbidity and decreased performance [1]. They can
also be spread to other athletes, putting them at risk for similar disease and
complications. The sports medicine physician may face challenging issues re-
garding infectious diseases when dealing with teams or highly competitive ath-
letes who have difficulties taking time off to recover. One must treat the
individual sick athlete and take the necessary precautions to contain the spread
of communicable disease to the surrounding team, staff, relatives, and other
contacts.
The authors aim to translate recommendations in public health to practice in
a sports medicine setting. Sports physicians have an opportunity to see athletes
during adolescence and adulthood who might not come in for routine health
maintenance except when related to their sports. Primary prevention of infec-
tious disease, the ideal goal, deals with avoiding the development of the disease
before infection occurs. Immunizations are an example of primary prevention
and have been the most successful public health programs for disease prophy-
laxis. Secondary prevention for infection control involves prevention of spread
to others. Athletes are often exposed to many different people, travel to compete
in various environments locally and internationally, and engage in higher-risk
activities, often in close contact with others [2]. The authors discuss the preven-
tive strategies for infectious disease in sport, including (1) a review of immu-
nization recommendations and prophylaxis guidelines, (2) improvements in
personal hygiene and prevention of spread of infectious organisms by direct
contact, (3) insect-borne disease precautions, and (4) prevention of sexually
transmitted diseases (STDs). A special emphasis on immunizations focuses
on pertussis, influenza, and meningococcal prophylaxis.
*Corresponding author. E-mail address: lukea@orthosurg.ucsf.edu (A. Luke).
0278-5919/07/$ – see front matter ª 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.csm.2007.04.006 sportsmed.theclinics.com
322 LUKE & D’HEMECOURTPUBLIC HEALTH, INFECTIOUS DISEASES, AND SPORTS
Public health plays an insidious role in our everyday lives to keep individuals
safe from communicable diseases, accidents, environmental concerns, and
countless other dangers. Programs are most successful when a disease no lon-
ger becomes a worry for the population through active prevention strategies.
Much of our understanding comes from history and from recognizing the im-
minent dangers so we can prevent diseases from occurring the next time.
Medical reports from major athletic events provide examples of issues that
can be encountered by the sports medicine physician. Mass-gathering events,
such as the Olympics, highlight some of the concerns that can occur with sports
and infectious diseases. International athletes compete together from countries
with different endemic microorganisms and variable health care practices. For
example, an outbreak of measles occurred in a Special Olympics event in St.
Paul, Minnesota. The point of infection was suspected to be a track and field
athlete from Argentina, resulting in measles infections in 16 individuals from
7 different states [3]. An outbreak of influenza that occurred during the 1988
Calgary Olympics was believed to have possibly affected the performances
of some athletes [4]. The pneumococcal vaccine was recommended to athletes
before competing in the 1992 Barcelona Olympics because of resistant Strepto-
coccus pneumoniae strains endemic in Spain [5]. Medical reporting and surveil-
lance of infections are extremely important to attempt to contain spread of
disease. At the 1996 Atlanta Olympics, a priority of surveillance was to identify
unusual presentations and infectious disease outbreaks to actively implement
same-day medical and public health interventions [6].
It is an important responsibility of physicians to report specific infectious dis-
eases, especially if an outbreak is suspected (Box 1) [7]. Health professionals
should contact their local public health officer to determine whether other cases
are occurring and what precautions need to be taken in the event of a serious
outbreak. In the past few years, infections such as severe acute respiratory syn-
drome [8] have required the need of quarantine to help control the spread of
these dangerous diseases. Health care professionals should report all clinically
significant adverse events following immunization to the Vaccine Adverse
Events Reporting System [9].
ATHLETES ARE ‘‘HIGHER RISK’’
The risk of disease transmission depends on the infectious agent—for example,
whether it is spread by way of respiratory secretions, skin contact, or blood. In
the context of infections spread by aerosol droplets, ‘‘close contact’’ can mean
caring for or living with an infected patient or having a high likelihood of direct
contact with the respiratory secretions or body fluids of an infected patient. Ex-
amples of close contact include kissing or embracing, sharing eating or drinking
utensils, talking to someone within 3 ft, physical examination, and any other
direct physical contact between people. Close contact does not include activities
such as walking by a person or briefly sitting across from someone [10].
323PREVENTION OF INFECTIOUS DISEASES IN ATHLETESBox 1: Infectious diseases designated as notifiable at the national
level during 2004
Acquired immunodeficiency syndrome (AIDS)
Anthrax
Botulism
Brucellosis
Chancrodi
Chlamydia trachomatis, genital infection
Cholera
Coccidioidomycosis
Cryptosproidiososis
Cryptosporidiosis
Cyclosporiasis
Diphtheria
Ehrlichiosis
Human granulocytic
Human monocytic
Human, other or unspecified agent
Encephalitis/meningitis, arboviral
California serogroup
Eastern equine
Powassan
St. Louis
Western equine
West Nile
Enterohemorrhagic Escherichia coli (EHEC)
EHEC O157:H7
EHEC Shiga toxin-positive, serogroup non-O157
EHEC Shiga toxin-positive, not serogrouped
Giardiasis
Gonorrhea
Haemophilus influenzae, invasive disease
Hansen disease (leprosy)
Hantavirus pulmonary syndrome
Hemolytic uremic syndrome, postdiarrheal
Hepatitis A, viral, acute
Hepatitis B, viral, acute
324 LUKE & D’HEMECOURTHepatitis B, viral, chronic
Hepatitis B, perinatal infection
Hepatitis C, acute
Hepatitis C, virus infection (past or present)
Human immunodeficiency virus (HIV) infection
Adult (age 13 years)
Pediatric (age <13 years)
Influenza-associated pediatric mortalitya
Legionellosis
Listeriosis
Lyme disease
Malaria
Measles
Meningococcal disease
Mumps
Pertussis
Plague
Poliomyelitis, paralytic
Psittacosis
Q fever
Rabies
Animal
Human
Rocky Mountain spotted fever
Rubella
Rubella, congenital syndrome
Salmonellosis
Severe acute respiratory syndrome–associated coronavirus (SARS-CoV) disease
Shigellosis
Smallpoxa
Streptococcal disease, invasive, group A
Streptococcal toxic-shock syndrome
Streptococcus pneumoniae, invasive disease
Drug-resistant, all ages
Age <5 years
Syphilis
Syphilis, congenital
Box 1: (continued)
325PREVENTION OF INFECTIOUS DISEASES IN ATHLETESAthletes may share personal items (eg, towels, water bottles, and soap) and
equipment (eg, weights). They may live in dormitories or in hotel rooms while
traveling, which leads to close contact and high exposure to teammates. They
participate in higher-risk activities [2,11]. Fewer athletes practice safe sex, which
can lead to STDs in homosexual and in heterosexual individuals. Athletes also
use more illicit drugs and alcohol, which can place them at risk of intravenous
needle exposure [12,13]. Steroids, hormones, and vitamins are other substances
that some athletes are injecting [14,15]. Tattoos are popular among athletes,
which are another source of needle infection risk.
IMMUNIZATIONS
Active immunization involves the administration of all or part of a microorganism
or a modified product of that microorganism, such as an antigen or protein. This
administration stimulates an immune response to develop protection against fu-
ture exposure to the infection [16]. Although most vaccines are over 90% effec-
tive, they are not guaranteed to promote immune protection [16].
Immunizations typically involve inactivated vaccines or live, attenuated
viruses. Inactivated vaccines include killed virus or bacterial proteins to stimu-
late one’s immune system to develop antibodies to any similar virus or bacteria.
More side effects are associated with the live, attenuated viruses—typically local
pain and, rarely, hypersensitivity reactions to vaccine constituents. A mild
febrile illness, a recent exposure to an infectious disease, pregnancy, breastfeed-
ing, nonspecific allergies, and family history of an adverse event after immuni-
zation, including seizures, are NOT contraindications for immunization [16].
Tetanus
Toxic-shock syndrome (other than streptococcal)
Trichinellosisb
Tuberculosis
Tularemia
Typhoid fever
Vancomycin-intermediate Staphylococcus aureus infection (VISA)c
Vancomycin-resistant Staphylococcus aureus infection (VRSA)c
Varicella
Varicella deaths
Yellow fever
aNew for 2004, as of October 4, 2004.
bFormerly referred to as trichinosis.
cNew for 2004, as of January 1, 2004.
From Jajosky RA, Hall PA, Adams DA, et al. Summary of notifiable diseases—United States,
2004. MMWR Morb Mortal Wkly Rep 2006;53(53):1–79.
Box 1: (continued)
326 LUKE & D’HEMECOURTSports medicine physicians need to consider the following indications for
immunizations (Tables 1 and 2): (1) routine health maintenance; (2) catch-up
immunizations for failed or missed immunizations; (3) immunizations of high
risk groups (ie, splenectomy, chronic disease, immunocompromised); (4) travel
to an endemic area; (5) close contact with an infected individual, or (6) recent
potential exposure to an infectious agent.
When doing preparticipation physical examinations, it is sometimes assumed
that athletes have received all their immunizations. Proof of immunizations is
required by schools and colleges, although exceptions can be given to individ-
uals refusing to receive immunizations. In a study surveying 69,115 Minnesota
children who entered kindergarten in 1992, by 19 months of age, 73% of stu-
dents had received the measles, mumps, and rubella (MMR) vaccine, and only
39% had received their fourth dose of diphtheria, tetanus, and pertussis vaccine
(DTaP) [17]. Vaccination rates can vary substantially by age, race/ethnicity,
and neighborhood [17]. White, non-Hispanic students usually have higher vac-
cination rates than children of other racial/ethnic groups. It has been estimated
that 79% of whites, 76% of Hispanics, and 71% of African Americans are fully
immunized [18].
Measles, Mumps, and Rubella
Although MMR vaccines have been administered for many decades and inci-
dences of disease are presently low [7], the diseases can still occur in the adult
population. Between 1986 and 1989, 6% of the measles cases occurred in college
Table 1
Routine immunizations for adults recommended by the Centers for Disease Control and
Prevention, October 2006–September 2007
Age group (y)
Vaccine 19–49 50–64 65
Tetanus, diptheria, pertussis
(Td/DTaP)
1-dose Td booster
every 10 y
Substitute 1 dose of DTaP for Td
Human papilloma virus (HPV) 3 doses (female patients)
Measles, mumps, rubella
(MMR)
1 or 2 doses 1 dose
Varicella 2 doses (0, 4–8 wk) 2 doses (0, 4–8 wk)
Influenza 1 dose annually 1 dose annually
Pneumococcal
(polysaccharide)
1–2 doses 1 dose
Hepatitis A 2 doses (0, 6–12 mo
or 0, 6–18 mo)
Hepatitis B 3 doses (0, 1–2, 4–6 mo)
Meningococcal 1 or more doses
Data fromUnited States Department of Health and Human Services, Centers for Disease Control and Prevention.
Recommended adult immunization schedule, by vaccine and age group. Available at http://www.cdc.gov/
vaccines/recs/schedules/downloads/adult/06-07/adult-schedule-11x17.pdf;AccessedNovember30,2006.
327PREVENTION OF INFECTIOUS DISEASES IN ATHLETESstudents [19]. Enzyme-linked immunosorbent assay tests for antibodies to MMR
are available to detect for immunization status [19]. In a series of 256 students, 53
(21%) were found to be seronegative to measles alone, 13 (5%) were seronegative
to rubella alone, and 5 (2%) were seronegative to measles and rubella. Eighty-six
percent of the individuals seronegative to measles had previously received a dose
of measles vaccine. Following a second injection, conversion to seropositive sta-
tus rose to 97% and 100% for measles and rubella, respectively. These data sup-
port the need for a two-dose vaccine schedule [19].
Pneumococcal Vaccine
Pneumococcal vaccine is administered to prevent Streptococcus pneumoniae infec-
tions. A conjugate heptavalent is given to during the first 2 years of life. A poly-
saccharide vaccine is provided to high-risk individuals older than 2 years
Table 2
Catch-up immunization schedule for children aged 7 through 18 years recommended by the
Centers for Disease Control and Prevention
Minimum interval between doses
Vaccine Dose 1 to dose 2 Dose 2 to dose 3 Dose 3 to booster dose
Tetanus, diptheria
(Td)h
4 wk 6 mo 6 mo if first dose given
at age <12 mo and
current age <11 y,
otherwise 5 y
Inactivated poliovirus
(IPV)b,j
4 wk 4 wk IPVb,i
Hepatitis B (HepB)c 4 wk 8 wk (and 16 wk
after first dose)
Measles, mumps,
rubella (MMR)d
4 wk
Varicellaj 4 wk
aDTaP. The fifth dose is not necessary if the fourth dose was administered after the fourth birthday.
bIPV. For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not neces-
sary if a third was administered at age 4 years. If OPV and IPV were administered as part of a series, then
a total of four doses should be given, regardless of the child’s current age.
cHepB. Administer the three-dose series to all children and adolescents <19 years of age if they were
not previously vaccinated.
dMMR. The second dose of MMR is recommended routinely at age 4 to 6 years but may be adminis-
tered earlier if desired.
eHib. Vaccine is not generally recommended for children aged 5 years.
fHib. If current age <12 months and the first 2 doses were Haemophilus b conjugate vaccine (PRP-OMP)
(pedvaxHIB or ComVax [Merck]), then the third (and final) dose should be administered at age 12 to 15
months and at least 8 weeks after the second dose.
gPCV. Vaccine is not generally recommended for children aged 5 years.
hTd. Adoloscent tetanus, diptheria, and pertussis vaccine (DTaP) may be substituted for any dose in a pri-
mary catch-up series or as a booster if age appropriate for DTaP. A 5-year interval from the last Td dose is
encouraged when DTaP is used as a booster dose. See ACIP recommendations for further information.
iIPV. Vaccine is not generally recommended for persons aged 18 years.
jVaricella. Administer the two-dose series to all susceptible adolescents aged 13 years.
Data from United States Department of Health and Human Services, Centers for Disease Control and Pre-
vention. 2007 Child & Adolescent Immunization Schedules. Available at http://www.cdc.gov/vaccines/
recs/schedules/downloads/child/2007/child-schedule-color-print.pdf; Accessed November 30, 2006.
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ease [20]. High-risk groups include patients who have asplenia, sickle cell dis-
ease, diabetes mellitus, cirrhosis, immunocompromised states, chronic cardiac
or pulmonary disease, or age 65 years or older. Immunity following vaccina-
tion is successful for periods of 5 to 10 years, requiring booster injections [20].
Hepatitis B
Hepatitis B is a blood-borne virus transmitted through sexual contact and par-
enteral exposure to blood and blood components [14]. Hepatitis B has a greater
risk for transmission in sports than HIV. The risk of HIV transmission is esti-
mated to between 1 in 1 million games and 1 in 85 million games [14,21]. The
risk arises if bleeding and skin exudates from an infected individual come into
contact with open wounds in another athlete, particularly during contact and
collision sports. There are no confirmed cases of spread of HIV through sports
[14]; however, 5 out of 10 high school sumo wrestlers at one club developed
hepatitis B [22]. Another case series reported on 11 of 65 American football
players who developed hepatitis B over a period of 19 months [23]. Contact
through open wounds, cuts, and abrasions were the suspected routes of
transmission.
Primary prevention
Although hepatitis A is a considered immunization in athletes who are traveling
to endemic areas, routine vaccination for hepatitis B is recommended for all in-
dividuals after birth using single or combination vaccines [24]. A three-dose im-
munization schedule is typically used after 18 years of age, with injections at
0 months, 1 month, and 6 months, although there is an optional four-dose
schedule [25]. The licensed vaccines have had 90% to 95% efficacy of prevent-
ing hepatitis B, with immunity lasting 15 years or longer [25]. Immunizations
for hepatitis B should be checked during the preparticipation physical examina-
tion, and catch-up immunizations recommended to the individual (see Table 2).
If individuals are uncertain about their immunization status, serologic testing
for antibody to hepatitis B surface antigen can determine immunity.
Secondary prevention
When athletes are known to be infected with hepatitis B, secondary prevention
includes education on personal hygiene, appropriate management of open
wounds, proper use of protective equipment, safe sex practices using a condom,
and avoidance of intravenous blood transmission (eg, through needle sharing
and illicit drug use).
Pertussis, Tetanus, and Polio
Bordetella pertussis, which is responsible for whooping cough, is a gram-negative
coccobacillus transmitted by way of airborne droplets [26]. Although tetanus
and polio have been controlled well with the use of vaccines [7], the rate of per-
tussis cases has been increasing in adolescents and adults despite routine immu-
nizations [27]. Most cases occur in patients 10 years or older [28].
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plete until older ages. The spread to infants is typically from adults. Pertussis
usually presents with nonspecific upper respiratory tract infection symptoms
for 1 to 2 weeks (catarrhal stage), after which the paroxysmal and sometimes
uncontrollable cough develops [26]. The cough is not necessarily always fol-
lowed by the classic ‘‘whooping’’ sound, and pertussis should be considered
with any persistent, prolonged cough.
Primary prevention
The whole-cell pertussis vaccine is estimated to be approximately 85% effective
[29]. This vaccine is still recommended for use in the routine immunization of
young children; however, the immunity provided begins to decline at 4 to 12
years following vaccination, which makes adolescents and adults susceptible
[27]. Rare adverse reactions from the vaccine include hypotonic, hyporespon-
sive episodes, high fever, seizures, and anaphylaxis [26]. Two acellular vaccines
have been introduced that are as effective as whole-cell vaccines and have fewer
adverse reactions [30]. These vaccines are combined with tetanus toxoid and
reduced diphtheria toxoid (DTaP). The Centers for Disease Control and Pre-
vention (CDC) recommends use of these DTaP boosters rather than the teta-
nus-diptheria (Td) booster starting after 11 to 12 years of age [31].
Secondary prevention
For pertussis, individuals are most contagious during the first 1 to 2 weeks dur-
ing the catarrhal stage but should be considered contagious until 3 weeks after
the paroxysmal stage ends or after taking antibiotics for 5 days [32]. Diagnosis
of pertussis infection is best performed through polymerase chain reaction as-
say (sensitivity, 94%; specificity, 97%) or through direct fluorescent antibody
testing (sensitivity, 52%; specificity, 98%). Nasal swab cultures (sensitivity,
15%; specificity, 100%) are routinely performed; however, they have high false
negative rates and take 7 to 12 days to yield results [33]. Physicians in the
United States are legally required to report cases of pertussis to state public
health departments [26]. It is estimated that 80% of susceptible household con-
tacts will be infected after close contact [26]. Antibiotic prophylaxis is recom-
mended for close contacts of persons who have pertussis to prevent
outbreaks [34]. Preferred drugs are azithromycin for 5 days, clarithromycin
for 7 days, or trimethoprim-sulfamethoxazole or erythromycin for 14 days,
which are similar for prophylaxis and treatment [34].
Influenza
Influenza presents with constitutional symptoms of fever, chills, malaise, fa-
tigue, and myalgia in addition to upper respiratory tract symptoms of a sore
throat, cough, and rhinitis. Rarely, more serious conditions can occur, includ-
ing encephalopathy, transverse myelitis, myocarditis, and pericarditis [9]. Im-
munogenicity is determined by hemaglutinins and neuraminidases on the
virus surface. Antigenic drift can occur that can mutate the virus into different
330 LUKE & D’HEMECOURTstrains. Transmission occurs by way of respiratory droplets. The virus has an
incubation period of usually 2 days (range, 1–4 days), and adults are infectious
from the day before symptoms begin to approximately 5 days after the illness
starts [9]. Symptoms usually last a week, although less likely, symptoms can last
longer than 2 weeks. These symptoms can be very disruptive for treatment and
challenging for the athlete to keep training and competing. A case series of 81
students, mostly healthy adolescents at a ski school in Austria, reported a severe
outbreak of influenza A, leading to an attack rate of 49%, with 69% becoming
ill within 2 days of the outbreak. Two students were hospitalized with pneumo-
nia and 1 died [35].
Primary prevention
Influenza vaccines contain strains of antigenically equivalent strains of influ-
enza similar to those annually recommended: influenza A (H3N2), influenza
A (H1N1), and a B virus. Depending on the emergence and spread of new
strains, other virus strains can be added to update the vaccine [9]. The efficacy
of influenza vaccine is approximately 70% to 90% for individuals under age 65
years [36]. Vaccination for influenza should occur in the fall (October or No-
vember), at the beginning of the flu season (Box 2) [9]. Antibodies develop
approximately 2 weeks after vaccination [9,37].
Inactivated influenza vaccine is generally appropriate for all populations re-
quiring influenza vaccine. Three influenza vaccines were available in the
United States for the 2006 to 2007 season: Fluzone (manufactured by Sanofi-
Pasteur); Fluvirin (manufactured by Novartis); and Fluarix (manufactured
by GlaxoSmithKline). The typical dose is 0.5 mL administered intramuscu-
larly, usually in the deltoid muscle. Live, attenuated influenza vaccine
(LAIV) is approved for use in healthy, nonpregnant individuals aged 5 to 49
Box 2: Indications for influenza vaccine
1. Adults and children with chronic disorders of the cardiorespiratory system, in-
cluding asthma
2. Adults and children who have chronic disease which may require regular
medical follow-up or hospitalization, including immunodeficiency
3. Young children aged 6–23 months
4. Children aged 6 months to 18 years on long-term aspirin therapy and at risk
for Reye’s syndrome
5. Persons aged >65 years
6. Residents of nursing homes or chronic-care facilities
7. Health care workers
8. Travelers to influenza-endemic areas
Adapted from Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza:
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR
Recomm Rep 2006;55(RR-10):1–42.
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(FluMist, manufactured by MedImmune). Individuals who have a hypersensi-
tivity or anaphylactic reaction to components of the flu vaccine or to eggs
should not be vaccinated [9].
Adults reported having a 19% reduction in severe febrile illnesses after LAIV
compared with placebo [38]. Side effects from LAIV increased in adults within
7 days of immunization compared with placebo and consisted mainly of nasal
congestion (44.5% versus 27.1%) and sore throat (27.8% versus 17.1%), which
lasted, on average, 2 days. Less common complaints were tiredness, cough, and
chills. There was no significant difference in the number of mild febrile illnesses
between immunization and placebo groups [39]. Injections can be scheduled to
occur at the optimum time during the athlete’s competitive schedule to mini-
mize concern about side effects.
When inactivated influenza vaccine shortages occurred in previous years,
the vaccine was recommended for high-risk groups as priority; however, the
general recommendation now is to offer the immunization annually to anyone
who wishes to reduce the likelihood of being ill with influenza or transmitting
the virus if they should become infected [9]. Although this policy cannot be di-
rectly translated into a benefit for the athlete, depending on the level of athlete,
the use of the LAIV may also be beneficial to prevent lost time from sport. In-
fluenza vaccine has been suggested for competitive athletes and essential per-
sonnel, especially before international events occurring during the influenza
season [4,40].
Secondary prevention
Treatment with antiviral medications can reduce the duration of uncompli-
cated influenza A and B illness by approximately 1 day when administered
within 2 days of illness onset [41,42]. Recommended antiviral treatment should
be given for 5 days [9]. Four antiviral agents are currently available: amanta-
dine, rimantadine, zanamivir, and oseltamivir [9]. The influenza A virus, how-
ever, has become resistant to amantadine and rimantadine, which are presently
not recommended to be used as first-line drugs [43]. Zanamivir (Ralenza, dry
powder taken by orally inhaled route) and oseltamivir (Tamiflu, capsule or oral
suspension) are neuraminidase inhibitors and can be used to treat patients and
to control influenza outbreaks in closed settings. Although typically used in
nursing homes, an outbreak in a dormitory may require chemoprophylaxis
[9]. There are limited data to suggest that serious complications from influenza,
such as lower respiratory tract infections, may be reduced [44]. The use of an-
tiviral medications for prophylaxis of influenza is unclear and is not yet recom-
mended for routine seasonal control [45]. The use of oseltamivir, however, has
been recommended in specific cases, especially if there is high risk of spread
such as household contacts and if individuals have not been immunized [46].
Oseltamivir was used to treat 36 of 188 patients, including 13 athletes during
the 2002 Salt Lake City Winter Olympics, with medications given to close con-
tacts, which was believed to limit the spread of influenza [47].
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ing influenza. Rapid swab tests are available and take approximately 30 min-
utes to detect the influenza virus. The tests are less sensitive (72%–95%) and
specific (76%–86%) than the traditional viral cultures [48]. They have moderate
sensitivities for influenza antigens and are more likely to produce false negative
rather than false positive results [48,49]. Direct and indirect fluorescent anti-
body staining tests are also available, but they are ordered more in hospitals
because they take 2 to 4 hours to obtain results [49]. Viral cultures are still
the ‘‘gold standard’’ for confirming the presence of influenza and identifying
the strains and subtypes [9].
Meningitis
Neisseria meningitides is a serious concern, especially for the adolescent and col-
lege populations. An alarming trend during the 1970s demonstrated an in-
crease in meningitis deaths in college students, with living in dormitories
being a risk factor. The disease can be spread by asymptomatic carriers. Stu-
dents living in dormitories were 9 to 23 times more likely of getting infected
than those living in other types of accommodations [50]. Freshmen who lived
in dormitories had an elevated risk of meningococcal disease (odds ratio, 3.6;
95% confidence interval, 1.6–8.5; P ¼ .003) compared with other college stu-
dents [51]. Aside from the risk of death, 11% to 19% of survivors of menin-
gitis have serious sequelae such as neurologic disability, limb loss, and
hearing loss [50].
Primary prevention
Routine vaccination with meningococcal vaccine is recommended for college
freshmen living in dormitories and for other populations at increased risk.
The CDC Advisory Committee on Immunization Practices recommends rou-
tine vaccination of young adolescents (11–12 years old) with meningococcal
vaccine (MCV4) at the preadolescent health care visit [50]. Therefore, sports
medicine physicians may be faced with higher frequency of checking for me-
ningococcal immunization status for high school and college athletes. A tetrava-
lent conjugate vaccine (Menactra, Sanofi Pasteur) is available against Neisseria
meningitidis isolates A, C, Y, and W-135 in a 0.5-mL single-dose vial. Over
the age of 11 years, 75% of the meningococcal infections are caused by strains
C, Y, or W-135 (CDC, unpublished data, 2004) [50]. Another vaccine, Meno-
mune (Aventis Pasteur Limited), has been licensed since 1981 and has a similar
immunogenicity profile to Menactra and is delivered subcutaneously as a 0.5-
mL dose. Menactra and Menomune have serum bactericidal protection rang-
ing from 89.4% and 94.4% for strain W-135 and 73.5% and 79.4% for strain
Y, respectively [50]. Revaccination may be necessary for individuals at high
risk after 5 years [52,53]. Common side effects with MCV4 were local pain
in just over 50% of patients, followed by swelling, induration, and redness in
approximately 10.8% to 17.1%. Fever was reported in 5.1% of children 18
years old or younger and in 1.5% of adults [50].
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Close contacts are at high risk and should be treated with chemoprophylaxis ide-
ally within 24 hours of identifying the index patient [50]. The goal of treatment is
to reduce nasopharyngeal carriage of Nmeningitidis. After more than 14 days after
the onset of illness in the index patient, chemoprophylaxis is not necessary [50].
A single dose of ciprofloxacin (500 mg orally) or ceftriaxone (250 mg by intra-
muscular injection), or rifampin (600 mg twice a day for 2 days) is recommended
for adults. Children between 1 month and 18 years old may take rifampin (10
mg/kg every 12 hours for 2 days), or ceftriaxone (125 mg intramuscularly) if
younger than 15 years [50]. One dose of azithromycin (500 mg) was also shown
to eradicate N meningitidis and may represent another treatment option [54].
Human Papillomavirus
Human papillomavirus (HPV) is associated with 99% of cervical cancers and
anogenital, head and neck, and nonmelanoma skin cancers. It is an STD
and can be diagnosed by abnormal cervical cell changes seen on Pap smear
[55]. This is a common infection, especially in sexually active adolescents
and university students [56].
Primary prevention
Primary prevention is now possible with two new vaccines: a bivalent vaccine
against HPV types 16 and 18 and a quadravalent vaccine against types 6, 11,
16, and 18. The vaccines have a three-dose schedule: 0, 1, and 6 months (bi-
valent vaccine) and 0, 2, and 6 months (quadravalent vaccine). At 4.5 years,
the bivalent vaccine was effective for producing a persistent antibody response
against HPV 16 and 18, with more than 98% seropositivity and 96.9% effec-
tiveness (95% confidence interval, 81.3–99.9) in reducing the number of re-
ported abnormalities on Pap smear, colposcopy, or both [57]. Routine
vaccination with three doses of quadrivalent HPV vaccine is recommended
for girls 11 to 12 years old but can be started in girls as young as 9 years. Girls
and women aged 13 to 26 years who have not been vaccinated previously or
who have not completed the full vaccine series are recommended to receive
a catch-up series. The vaccine is intended to be administered before potential
exposure to HPV through sexual contact [58].
Secondary prevention
Secondary prevention involves checking the affected individual’s partners for
signs of genital warts and other STDs. Regular cervical screen is recommen-
ded. Use of condoms and education on spread is important. HPV infection per-
sists for life; however, the degree and duration of contagiousness is yet
unknown [59].
Travel Immunizations
Athletes traveling need to consider the endemic diseases in the geographic lo-
cation where they are competing. They should be aware of risks of acquiring
common diseases, their accommodations (urban versus rural), local foods, and
334 LUKE & D’HEMECOURTcustoms. Immunizations should ideally be planned 4 or more months in ad-
vance to allow for adequate time to administer vaccines (Table 3). There are
many resources for information about prevention of infectious diseases for
travelers (Table 4).
Table 3
Recommended immunizations for travelers to developing countriesa
Length of travel
Immunizations
Brief,
<2 wk
Intermediate,
2 wk to 3 mo
Long-term
residential, >3 mo
Review and complete
age-appropriate
childhood schedule (see
text for details)
þ þ þ
DTaP, poliovirus,
pneumococcal, and
Haemophilus influenzae
type b vaccines may be
given at 4-wk intervals if
necessary to complete the
recommended schedule
before departure
Measles: 2 additional
doses given if younger
than 12 mo of age
at first dose
Varicella
Hepatitis Bb
Yellow feverc þ þ þ
Hepatitis Ad þ þ þ
Typhoid fevere  þ þ
Meningococcal diseasef   
Rabiesg  þ þ
Japanese encephalitish   þ
þ ¼ recommended;  ¼ consider.
aSee disease-specific chapters in Section 3 of the AAP Red Book for details: [Red Book: 2006 report of
the Committee of Infectious Diseases. 27th edition. Elk Grove Village, (IL) American Academy of Pediatrics;
2006]. For further sources of information, see text.
bIf insufficient time to complete 6-month primary series, accelerated series can be given (see text for
details).
cFor regions with endemic infection.
dIndicated for travelers to areas with intermediate or high endemic rates of HAV infection.
eIndicated for travelers who will consume food and liquids in areas of poor sanitation.
fRecommended for regions of Africa with endemic infection and during local epidemics, and required
for travel to Saudi Arabia for the Hajj.
gIndicated for people with high risk of animal exposure (especially to dogs) and for travelers to countries
with endemic infection.
hFor regions with endemic infection. For high-risk activities in areas experiencing outbreaks, vaccine is
recommended, even for brief travel.
From American Academy of Pediatrics. International travel. In: Pickering LK, editor. Red book: 2006
report of the committee on infectious diseases. 27th edition. Elk Grove Village (IL): American Academy
of Pediatrics; 2006. p. 99; with permission from the American Academy of Pediatrics.
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Mosquito-Borne Disease
A number of arthropods, such as mosquitoes and ticks, can transmit diseases.
Mosquito-vector diseases include West Nile virus, yellow fever virus, and den-
gue virus. West Nile virus, a flavivirus, has demonstrated a seasonally endemic
epidemiology with geographic variation in the United States, especially in Cal-
ifornia, Arizona, and Colorado [7,61]. This disease typically presents between
July and October, although cases have presented between April and December.
The prevention of mosquito bites is the cornerstone of prevention. An athlete
in an endemic area should wear an insect repellant such as deet (N,N-diethyl-m-
toluamide), picaridin (KBR-3023), or oil of lemon eucalyptus (p-menthane-3,8
diol). Deet and permethin may be applied to the clothing [62]. If a sunscreen
is used concomitantly, the insect repellant should be applied on top of this
and removed at the end of the day. Long-sleeved shirts that are tucked into
long pants are also useful.
Tick-Borne Disease
Tick-borne diseases include rickettsial diseases, Lyme disease, babesiosis, tick-
borne relapsing fever, and occasionally, tularemia and Q fever (Table 5).
Table 4
More common tick-borne diseases
Tick-borne disease Organism
Common vector (geographic
area)
Rocky Mountain spotted fever Rickettsia rickettsii Dog tick, Dermacentor variabilis
(central, Pacific coastal, and
eastern US)
Rocky Mountain wood tick,
Dermacentor andersoni
(western US)
Human monocytotropic
ehrlichiosis
Ehrlichia chaffeensis Lone Star tick (south central US in
Maryland, Arkansas,
Tennessee, Oklahoma, and
Missouri) [60]
Human granulocytotropic
anaplasmosis
Anaplasma
phagocytophilum
Blacklegged tick, Ixodes
scapularis (north central US
and New England)
Ixodes pacificus (California) [75]
Lyme disease Borrelia burgdorferi Ixodes scapularis (eastern US in
New England and mid-Atlantic
states and Midwest US in
Wisconsin and Minnesota)
Ixodes pacificus (west in northern
California)
Babesiosis Parasite, Babesia
microti
Ixodes scapularis (northeast of
the US)
Abbreviation: US, United States.
336 LUKE & D’HEMECOURTCertain athletes who participate in rural outdoor activities are more susceptible
to tick bites. These sports include cross-country running, training in multiple
sports in rural areas, and recreational outdoor sports such as fishing and hiking.
Children are more at risk to tick bites.
Three more common rickettsial illnesses are Rocky Mountain spotted fever,
human monocytotropic ehrlichiosis, and human granulocytotropic anaplasmo-
sis [60]. The infectious organisms responsible for these illnesses maintain their
lifecycles in mammals and ticks. Their prevalence reflects the geographic loca-
tions and the seasonality of the tick abundance. Their season is usually from
April to September, but they can present throughout the year. Newer rickettsial
diseases are emerging. These potentially lethal diseases are difficult to diagnose
because they often mimic viral syndromes. As many as 60% to 75% of patients
are initially misdiagnosed [63,64].
With Rocky Mountain spotted fever, more than 50% of cases are reported in
the five states of North Carolina, South Carolina, Tennessee, Oklahoma, and
Arkansas [65]. The presentation most often manifests as a sudden febrile illness
with headache, myalgia, and a maculopapular rash that spreads in a centripetal
pattern. Rickettsia rickettsii has a predilection for endothelial cells and can cause
Table 5
Suggested resources for preventing infections
Topic Web site
Vaccines licensed for immunization and
distribution in the United States
www.fda.gov/cber/vaccine/licvacc.htm
http://www.vaccineinformation.org/
How to store and handle vaccines www.cdc.gov/nip/menus/
vaccines.htm#Storage
Adult immunization schedule http://www.cdc.gov/nip/recs/
adult-schedule.htm
Travel information www.cdc.gov/travel
www.who.int/ith
Children and adolescents immunization
schedule
http://www.cdc.gov/nip/recs/
child-schedule.htm
HIV position statements http://www.fims.org/ (International
Federation of Sports Medicine)
http://www.casm-acms.org/forms/
statements/HIVEng.pdf (Canadian
Academy of Sport Medicine)
http://www.amssm.org/hiv.html
(American Medical Society for Sports
Medicine and the American
Orthopaedic Society for Sports
Medicine)
Morbidity and Mortality Weekly Reports www.cdc.gov/mmwr
Primer for physicians for preventing
food-borne illnesses
http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr5002a1.htm
Web sites accessed November 3, 2006.
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on clinical presentation, with epidemiologic, geographic, and seasonal consider-
ations. Laboratory testing may be supportive with thrombocytopenia and mild
liver enzyme elevation. Serologic testing is supportive only on a delayed basis
with acute and convalescent titers. Human monocytotropic ehrlichiosis and hu-
man granulocytotropic anaplasmosis can also present with acute headache,
fever, and myalgia. Laboratory evaluation often demonstrates leukopenia,
thrombocytopenia, and transaminase elevation.
Common tick-borne illnesses that have been reported in the northeast
United States are Lyme disease and babesiosis, which are transmitted by the
tick Ixodes scapularis [66]. Babesiosis can cause a febrile illness and possibly
life-threatening anemia and thrombocytopenia. Lyme disease is a rickettsial dis-
ease caused by Borrelia burgdorferi. As such, concurrent disease may be caused
by the same tick bite (see Table 4).
Tick-bite prevention
There are no proven vaccines for these tick-borne illnesses, but all are prevent-
able by careful vigilance and protection. The key to prevention is to under-
stand the regional epidemiology and seasonality of the diseases. Vaccination
for Lyme disease (LYMErix) was originally approved; however, the manufac-
turer took the vaccine off the market due to declining sales. There was a 49%
efficacy after two doses and a 76% efficacy after three doses [67]; however, the
protection diminished after 2 years.
Ticks thrive in a wooded environment and at the edge of woods with sur-
rounding high vegetation. Ticks are uncommon in well-mowed lawns. Relative
tick-free zones can be created by placing wood chips or gravel around recrea-
tional areas to separate the woods [68]. Other landscape management tips in-
clude removing clippings and leaves, keeping stone walls clean of leaves, and
restricting the use of groundcover, such as pachysandra, where pets and chil-
dren may play. Widening woodland trails andkeeping in the center of the trail
while walking may be helpful. When traveling in wooded areas, light-colored
clothing is helpful to identify the tick. Long pants tucked into tightly woven
socks and closed shoes minimize exposure. Deet at 10% to 25% should be ap-
plied to the skin. Permethrin may be applied only to the clothing. Clothes
should be removed and cleaned and dried after exposure. The clothes dryer
is effective in killing ticks. One should carefully check for ticks in the nymphal
phase that may be the size of a pin head. Careful inspection should be done of
the hair, ears, axilla, belly button, and legs. Children and pets should also be
checked. It is also important to monitor pets that may travel in the woods
and return indoors.
The technique of tick removal is critical. Tweezers with fine tips should be
used close to the skin and pulled directly away. Squeezing the body may allow
contamination of the disease into the host [69]. Lyme disease is not contracted
until at least 24 hours of tick adherence [70]; however, ehrlichiosis may trans-
mit in less than 24 hours. Preventive antibiotics are generally not indicated
338 LUKE & D’HEMECOURTbecause less than 5% of bites are Lyme infected, especially with a flat tick. After
a high-risk exposure (when the tick has been engaged for more than 24 hours
and is engorged), a single dose of 200 mg of doxycycline is believed to be ef-
fective [71].
HYGIENE PRECAUTIONS AND INFECTION CONTROL
Personal Hygiene
Most infectious diseases are spread from contact with the microorganism directly
or indirectly from the infected individual. Athletes frequently interact with team-
mates, coaches, athletic trainers, and physicians and share equipment, water bot-
tles, towels, and supplies. This interaction is particularly a concern, with the
recent outbreaks of methicillin-resistent Staphylococcus aureus (MRSA) infections
among sports teams [72,73]. Three categories of potential risk factors for spread-
ing infection have been suggested: ‘‘sharing’’ (sharing soap/towels/water bottles
with teammates), ‘‘skin injury’’ (cuts, abrasions), and ‘‘close contact’’ (locker ad-
jacent to infected teammate, living on-campus) [74].
Good personal hygiene can help reduce colonization of bacteria. Bacterial
counts can range from 5000 to 5 million colony-forming units per square cen-
timeter on the hands [75]. Universal body fluid precautions—for example, using
disposable gloves when examining the oral cavity or wounds and frequent
hand washing—can reduce the risk of infection. MRSA is transmitted from
an infected patient to the gloves of a health care worker in approximately
17% (9%–25%). Physicians, in particular, have a low compliance for using
gloves and washing their hands [76]. Proper surgical hand washing is recom-
mended to be 15 to 30 seconds with soap, a 30-second rinse with water, fol-
lowed by complete drying with a towel. The use of rinses and gels with
concentrations of 50% to 95% alcohol take 15 seconds to use and are effective
at killing organisms [75]. The use of chlorhexidine soap has been useful for re-
ducing MRSA infections.
Viruses and bacteria can exist on equipment. MRSA was found in the taping
gel and whirlpool in the training facilities of a professional football team [72].
Using diluted bleach (1 part bleach in 9 parts water) to cleanse training areas
and equipment is recommended [8]. Routine cleaning schedules for shared
equipment should be established and recorded.
For upper respiratory tract infections, isolation of those who have had close
contact with someone who has a confirmed or suspected infection, especially
those who have active symptoms such as persistent fever and cough, is an ef-
fective and practical method of avoiding contact [8].
Any athlete who has a scratch, abrasion, or laceration or who has potentially
infectious skin lesions such as vesicular or weeping skin lesions should be re-
moved from play until the area can be securely covered with occlusive ban-
dages or dressings to prevent leakage of blood or serous fluid [77]. Uniforms
with fresh blood should be removed and replaced immediately after stopping
any bleeding. Bleach diluted with tap water in a 1:10 ratio can be used to
wash equipment that has had contact with blood or body fluid. Body substance
339PREVENTION OF INFECTIOUS DISEASES IN ATHLETESprecautions should be taken by health care professionals at all times when treat-
ing open wounds.
Prevention of Methicillin-Resistant Staphylococcus Aureus
One type of bacteria that has become more common in the hospital and a com-
munity-acquired infection is MRSA. Although contact sports such as wrestling
and football have been commonly associated with MRSA spread, this infection
has also been discovered in minimal-contact sports such as fencing [78]. Three
factors are associated with MRSA spread in sports. First, even with sports that
have minimal contact, there are often abrasions and chaffing from clothing and
hot environments. Second, equipment is often shared and there is potential for
transmission of bacteria. Third, many sports have sufficient skin-to-skin contact
to transmit organisms. Subsequently, health care providers should strongly en-
courage good overall and hand hygiene in addition to covering all wounds and
limiting shared equipment. It is crucial to have an ample supply of soap and
water and alcohol-based hand cleansers. Athletes, staff, and coaches should
be educated in proper first aid for wounds, in recognition of wounds that are
potentially infected, and in seeking medical attention for lesions that have con-
cerning signs, especially large pustules or boils.
Prevention of Fungal Rashes
Athlete’s foot, tinea pedis, is a common ailment not only during the hot sum-
mer months but also during the winter months with indoor sports. A number
of prevention items include washing feet daily; drying between the toes; wear-
ing cotton, nonsynthetic socks; wearing bathing shoes in public showers; and
wearing sandals in warmer weather. Jock itch, tinea cruris, is best prevented
by showering immediately after athletic endeavors and wearing cotton briefs.
A good talc powder may be used for prevention of athlete’s foot and jock
itch. Ring worm, tinea corporis, is best prevented by avoiding contact. Contact
athletes such as wrestlers should not participate until any lesions have cleared
or can be safely and effectively covered.
SEXUALLY TRANSMITTED DISEASE PREVENTION
Athletes may manifest risk-taking behavior and subsequently be at increased
risk for STDs [2]. The preparticipation examination affords the opportunity
for the clinician to address these concerns. The CDC has emphasized the
five intervention strategies [79], which include education on sexual behavior,
identification of asymptomatic individuals, diagnosis and treatment of infected
individuals, counseling of sexual partners of persons who have an STD, and
pre-exposure vaccination when applicable. Individuals at risk should be ques-
tioned about partners regarding number and same or opposite sex. Information
about the type of sexual activity, the use of protection, and history of previous
STDs should also be identified.
Preventive measures for an STD include abstinence if an individual or part-
ner is actively infected and undergoing treatment. Pre-exposure prophylaxis is
relevant in several situations. Hepatitis B vaccine is recommended in all
340 LUKE & D’HEMECOURTindividuals potentially exposed to STDs. Hepatitis A vaccine is recommended
for all men who have sex with men or users of illicit drugs (injectable and non-
injectable). For girls and women aged 9 to 26 years, the new quadrivalent vac-
cine for HPV types 6, 11,16, and 18 is recommended due to the higher
associated risk of cervical cancer.
Most condoms are made of latex and are quite effective in STD prevention. In
one study of partners of HIV-infected individuals, partners were 80% less likely
to seroconvert than those who did not use condoms [80]. The male condom can
also reduce the transmission of gonorrhea, chlamydiosis, and trichomiasis [81].
There may be some added protection against herpes simplex virus 2 and
a 70% reduction of HPV transmission [82,83]. When an individual is allergic
to latex, certain polyurethane condoms are likely just as effective, although
they may break more readily. Conversely, natural-membrane condoms such
as lambskin are too porous to be used for STD prevention. Only water-based lu-
bricants should be used with latex condoms because oil bases will weaken the la-
tex. The female condom is a double-ringed polyurethane sheath that is used
vaginally and during anal receptive intercourse that is effective in limited trials
in preventing HIV/STDs [84,85]. Spermicides and nonbarrier contraception
have no role in STD prevention.
Finally, providers should encourage patients who have STDs to notify their
partners. Often, this notification is pursued by the public health department. In
the event of exposure to HIV by sexual exposure or needle stick, HIV prophy-
laxis is often undertaken and should be immediate. Prophylactic treatment usu-
ally involves the hospital infectious disease division to determine the best
combination therapy.
SUMMARY
Education is paramount in public health and in the prevention of infectious
diseases. Athletes are a high-risk population often due to their increased expo-
sure to different people and environments and, sometimes, their outgoing life-
style behaviors. Primary prevention can be promoted through accurate
immunizations; appropriate, planned health maintenance; good hygiene prac-
tices; and behavior modification to minimize high-risk activities. Secondary pre-
vention can be achieved through vigilant surveillance for reportable illnesses,
proper education and containment for reducing spread if an illness occurs,
and timely prophylaxis with medications and immunizations in certain cases.
References
[1] Roberts JA, Wilson JA, Clements GB. Virus infections and sports performance—a prospec-
tive study. Br J Sports Med 1988;22(4):161–2.
[2] Nattiv A, Puffer JC, Green GA. Lifestyles and health risks of collegiate athletes: a multi-center
study. Clin J Sport Med 1997;7(4):262–72.
[3] Ehresmann KR, Hedberg CW, Grimm MB, et al. An outbreak of measles at an international
sporting event with airborne transmission in a domed stadium. J Infect Dis 1995;171(3):
679–83.
[4] Tarrant M, Challis EB. Influenza vaccination for athletes? CMAJ 1988;139(4):282.
341PREVENTION OF INFECTIOUS DISEASES IN ATHLETES[5] Plasencia A, Segura A, Farres J, et al. Pneumococcal vaccine for Olympic athletes and vis-
itors to Spain. Barcelona Olympic Organizing Committee. N Engl J Med 1992;327(6):
437.
[6] Brennan RJ, Keim ME, Sharp TW, et al. Medical and public health services at the 1996
Atlanta Olympic Games: an overview. Med J Aust 1997;167(11–12):595–8.
[7] Jajosky RA, Hall PA, Adams DA, et al. Summary of notifiable diseases—United States,
2004. MMWR Morb Mortal Wkly Rep 2006;53(53):1–79.
[8] So RC, Ko J, Yuan YW, et al. Severe acute respiratory syndrome and sport: facts and falla-
cies. Sports Med 2004;34(15):1023–33.
[9] Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations
of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep
2006;55(RR-10):1–42.
[10] Centers for Disease Control and Prevention. Basic information about SARS. Available at:
http://www.cdc.gov/ncidod/SARS/factsheet.htm. Accessed November 3, 2006.
[11] Pate RR, Trost SG, Levin S, et al. Sports participation and health-related behaviors among US
youth. Arch Pediatr Adolesc Med 2000;154(9):904–11.
[12] Sklarek HM, Mantovani RP, Erens E, et al. AIDS in a bodybuilder using anabolic steroids.
N Engl J Med 1984;311(26):1701.
[13] Scott MJ, Scott MJ Jr. HIV infection associated with injections of anabolic steroids. JAMA
1989;262(2):207–8.
[14] Kordi R, Wallace WA. Blood borne infections in sport: risks of transmission, methods of
prevention, and recommendations for hepatitis B vaccination. Br J Sports Med
2004;38(6):678–84 [discussion: 678–84].
[15] Rich JD, Dickinson BP, Feller A, et al. The infectious complications of anabolic-androgenic
steroid injection. Int J Sports Med 1999;20(8):563–6.
[16] American Academy of Pediatrics, et al. Active and passive immunization. In: Pickering LK,
Baker CJ, Long SS, editors. Red book: 2006 report of the Committee of Infectious Diseases.
27th edition. Elk Grove Village (IL): American Academy of Pediatrics; 2006. p. 1–93.
[17] Ehresmann KR, White KE, Hedberg CW, et al. A statewide survey of immunization rates in
Minnesota school age children: implications for targeted assessment and prevention strate-
gies. Pediatr Infect Dis J 1998;17(8):711–6.
[18] Tallia AF, Ibsen KH, Howarth DF. Swanson’s family practice review: a problem-oriented ap-
proach. 5th edition. Philadelphia: Elsevier Inc.; 2005:468.
[19] Cote TR, Sivertson D, Horan JM, et al. Evaluation of a two-dose measles, mumps, and rubella
vaccination schedule in a cohort of college athletes. Public Health Rep 1993;108(4):
431–5.
[20] Mufson MA. Antibody response of pneumococcal vaccine: need for booster dosing? Int
J Antimicrob Agents 2000;14(2):107–12.
[21] Brown LS Jr, Drotman DP, Chu A, et al. Bleeding injuries in professional football: estimating
the risk for HIV transmission. Ann Intern Med 1995;122(4):273–4.
[22] Kashiwagi S, Hayashi J, Ikematsu H, et al. An outbreak of hepatitis B in members of a high
school sumo wrestling club. JAMA 1982;248(2):213–4.
[23] Tobe K, Matsuura K, Ogura T, et al. Horizontal transmission of hepatitis B virus among
players of an American football team. Arch Intern Med 2000;160(16):2541–5.
[24] Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate
transmission of hepatitis B virus infection in the United States: recommendations of the
Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants,
children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1–31.
[25] American Academy of Pediatrics, et al. Hepatitis B. In: Pickering LK, Baker CJ, Long SS, ed-
itors. Red book: 2006 report of the Committee of Infectious Diseases. 27th edition. Elk
Grove Village (IL): American Academy of Pediatrics; 2006. p. 169–71.
[26] Gregory DS. Pertussis: a disease affecting all ages. Am Fam Physician 2006;74(3):
420–6.
342 LUKE & D’HEMECOURT[27] Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after
natural infection or vaccination. Pediatr Infect Dis J 2005;24(Suppl 5):S58–61.
[28] Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases—United States,
2003. MMWR Morb Mortal Wkly Rep 2005;52(54):1–85.
[29] Olin P, Rasmussen F, Gustafsson L, et al. Randomised controlled trial of two-component,
three-component, and five-component acellular pertussis vaccines compared with whole-
cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet
1997;350(9091):1569–77.
[30] Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in
children. Vaccine 2003;21(17–18):2003–14.
[31] Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis
among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep 2006;55(RR-3):1–34.
[32] American Academy of Pediatrics, et al. Pertussis. In: Pickering LK, Baker CJ, Long SS,
editors. Red book: 2006 report of the Committee of Infectious Diseases. 27th edition.
Elk Grove Village (IL): American Academy of Pediatrics; 2006. p. 472–86.
[33] Loeffelholz MJ, Thompson CJ, Long KS, et al. Comparison of PCR, culture, and direct fluores-
cent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999;37(9):
2872–6.
[34] Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for the treatment and
postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep
2005;54(RR-14):1–16.
[35] Lyytikainen O, Hoffmann E, Timm H, et al. Influenza A outbreak among adolescents in a ski
hostel. Eur J Clin Microbiol Infect Dis 1998;17(2):128–30.
[36] Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care pro-
fessionals: a randomized trial. JAMA 1999;281(10):908–13.
[37] Brokstad KA, Cox RJ, Olofsson J, et al. Parenteral influenza vaccination induces a rapid sys-
temic and local immune response. J Infect Dis 1995;171(1):198–203.
[38] Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated,
cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis
2004;39(7):920–7.
[39] Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal in-
fluenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA
1999;282(2):137–44.
[40] Ross DS, Swain R, Thomas J. Study indicates influenza vaccine beneficial for college ath-
letes. W V Med J 2001;97(5):235.
[41] Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhib-
itor zanamivir in treating influenza virus infection in adults: results from Japan. GG167
Group. Antivir Ther 1999;4(2):61–8.
[42] Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treat-
ment and prevention of influenza A and B: systematic review and meta-analyses of rando-
mised controlled trials. BMJ 2003;326(7401):1235–43.
[43] Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza Aviruses isolated
early during the 2005–2006 influenza season in the United States. JAMA 2006;295(8):
891–4.
[44] Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower re-
spiratory tract complications and hospitalizations. Arch Intern Med 2003;163(14):
1667–72.
[45] Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic
review. Lancet 2006;367(9507):303–13.
[46] Uhnoo I, Linde A, Pauksens K, et al. Treatment and prevention of influenza: Swedish recom-
mendations. Scand J Infect Dis 2003;35(1):3–11.
343PREVENTION OF INFECTIOUS DISEASES IN ATHLETES[47] Gundlapalli AV, Rubin MA, Samore MH, et al. Influenza, winter Olympiad, 2002. Emerg
Infect Dis 2006;12(1):144–6.
[48] Rodriguez WJ, Schwartz RH, Thorne MM. Evaluation of diagnostic tests for influenza in a
pediatric practice. Pediatr Infect Dis J 2002;21(3):193–6.
[49] Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically
useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22(2):164–77.
[50] Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommen-
dations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep
2005;54(RR-7):1–21.
[51] Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in
college students. JAMA 2001;286(6):688–93.
[52] Control and prevention of meningococcal disease: recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-5):1–10.
[53] Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C
conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365–7.
[54] Girgis N, Sultan Y, Frenck RW Jr, et al. Azithromycin compared with rifampin for eradication
of nasopharyngeal colonization byNeisseria meningitidis. Pediatr Infect Dis J 1998;17(9):
816–9.
[55] Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and
low-grade squamous intraepithelial lesion development in young females. JAMA
2001;285(23):2995–3002.
[56] Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and
risk factors in a cohort of female university students. Am J Epidemiol 2003;157(3):218–26.
[57] Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent
L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from
a randomised control trial. Lancet 2006;367(9518):1247–55.
[58] CDC. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. Avail-
able at: http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf. Accessed November
9, 2006.
[59] American Academy of Pediatrics, et al. Human papillomaviruses. In: Pickering LK, Baker CJ,
Long SS, editors. Red book: 2006 report of the Committee of Infectious Diseases. 27th edi-
tion. Elk Grove Village (IL): American Academy of Pediatrics; 2006. p. 473–6.
[60] Carpenter CF, Gandhi TK, Kong LK, et al. The incidence of ehrlichial and rickettsial infection
in patients with unexplained fever and recent history of tick bite in central North Carolina.
J Infect Dis 1999;180(3):900–3.
[61] O’Leary DR, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United
States, 2002. Vector Borne Zoonotic Dis 2004;4(1):61–70.
[62] Barnard DR, Xue RD. Laboratory evaluation of mosquito repellents against Aedes albopic-
tus, Culex nigripalpus, and Ochierotatus triseriatus (Diptera: Culicidae). J Med Entomol
2004;41(4):726–30.
[63] O’Reilly M, Paddock C, Elchos B, et al. Physician knowledge of the diagnosis and manage-
ment of Rocky Mountain spotted fever: Mississippi, 2002. Ann N Y Acad Sci 2003;990:
295–301.
[64] Helmick CG, Bernard KW, D’Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory,
and epidemiological features of 262 cases. J Infect Dis 1984;150(4):480–8.
[65] Treadwell TA, Holman RC, Clarke MJ, et al. Rocky Mountain spotted fever in the United
States, 1993-1996. Am J Trop Med Hyg 2000;63(1–2):21–6.
[66] Herwaldt BL, McGovern PC, Gerwel MP, et al. Endemic babesiosis in another eastern state:
New Jersey. Emerg Infect Dis 2003;9(2):184–8.
[67] Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant
Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study
Group. N Engl J Med 1998;339(4):209–15.
[68] Couch P, Johnson CE. Prevention of Lyme disease. Am J Hosp Pharm 1992;49(5):1164–73.
344 LUKE & D’HEMECOURT[69] des Vignes F, Piesman J, Heffernan R, et al. Effect of tick removal on transmission of Borrelia
burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis
2001;183(5):773–8.
[70] Falco RC, Fish D, Piesman J. Duration of tick bites in a Lyme disease-endemic area. Am J Epi-
demiol 1996;143(2):187–92.
[71] Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the
prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345(2):
79–84.
[72] Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus
aureus among professional football players. N Engl J Med 2005;352(5):468–75.
[73] Lindenmayer JM, Schoenfeld S, O’Grady R, et al. Methicillin-resistant Staphylococcus au-
reus in a high school wrestling team and the surrounding community. Arch Intern Med
1998;158(8):895–9.
[74] Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant Staphylococcus aureus
infections in a football team. Emerg Infect Dis 2005;11(4):526–32.
[75] Gawande A. On washing hands. N Engl J Med 2004;350(13):1283–6.
[76] McBryde ES, Bradley LC, Whitby M, et al. An investigation of contact transmission of meth-
icillin-resistant Staphylococcus aureus. J Hosp Infect 2004;58(2):104–8.
[77] Mast EE, Goodman RA, Bond WW, et al. Transmission of blood-borne pathogens during
sports: risk and prevention. Ann Intern Med 1995;122(4):283–5.
[78] Gantz N, Harmon H, Handy J. Methicillin-resistant Staphylococcus aureus infections among
competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles
County, 2000–2003. MMWR Morb Mortal Wkly Rep 2003;52(33):793–5.
[79] Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006.
MMWR Recomm Rep 2006;55(RR-11):1–94.
[80] Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmit-
ted infections. Bull World Health Organ 2004;82(6):454–61.
[81] Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV
transmission risk behaviors and sexually transmitted diseases among women living with
HIV: the WiLLOW Program. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S58–67.
[82] Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of
herpes simplex virus type 2 from men to women. JAMA 2001;285(24):3100–6.
[83] Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papilloma-
virus infection in young women. N Engl J Med 2006;354(25):2645–54.
[84] French PP, Latka M, Gollub EL, et al. Use-effectiveness of the female versus male condom in
preventing sexually transmitted disease in women. Sex Transm Dis 2003;30(5):433–9.
[85] Gross M, Buchbinder SP, Holte S, et al. Use of reality ‘‘female condoms’’ for anal sex by US
men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team. Am J Pub-
lic Health 1999;89(11):1739–41.
